Surrozen, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SRZN Nasdaq 2830 www.surrozen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Surrozen, Inc.

We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business Growth - Jul 1st, 2025 6:51 am
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - May 14th, 2025 6:30 am
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - May 9th, 2025 2:05 pm
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - Mar 31st, 2025 2:05 pm
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases - Mar 24th, 2025 7:00 am
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation - Jan 22nd, 2025 4:08 am
Surrozen to Present at Upcoming Healthcare Investor Conferences - Nov 6th, 2024 2:30 pm
Surrozen Provides Third Quarter 2024 Financial Results and Business Update - Nov 6th, 2024 7:00 am
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis - Nov 4th, 2024 6:30 am
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - Sep 24th, 2024 6:30 am
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky - Aug 15th, 2024 4:21 am
Surrozen Provides Second Quarter 2024 Financial Results and Business Update - Aug 12th, 2024 2:05 pm